← Human Trials & Peer-Reviewed Studies
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study
Plain-language guide to PMID 28430638 (2017): pilot randomized controlled trial study of Somatostatin and Lanreotide in 71 patients.
Key Facts
- PMID
- 28430638
- Journal
- Oncotarget
- Year
- 2017
- Study type
- Randomized Controlled Trial
- Authors
- Tong H et al. (8 authors)
- DOI
- 10.18632/oncotarget.15684
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Somatostatin and Lanreotide.
Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis.
Cyclooxygenase-2 inhibitors and somatostatin analogues were reported to inhibit tumour angiogenesis.
Who Took Part
The abstract describes 71 patients taking part.
By PubMed's age tags, the people studied were teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
A total of 71 patients with HCC were enrolled and randomly assigned to either TACE (n=35) or TACE+C+L (n=36) group.
How the Study Was Run
The design is described as randomized and pilot.
The patients were allocated by chance, so the Somatostatin group and the comparison group should start out alike.
It is described as a pilot, a small early test of whether a larger Somatostatin study would be practical.
The methods mention a period of 3 years.
Overall survival, disease control rate (DCR), and adverse events were assessed during a 3-year follow-up period.
What Was Measured
The pilot randomized controlled trial was aimed to prospectively evaluate the protocol of TACE combined with celecoxib and lanreotide (TACE+C+L) in patients with unresectable and advanced HCC.
The subject headings attached to it are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Cause of Death, Celecoxib, Chemoembolization, Therapeutic, Chemotherapy, Adjuvant and Combined Modality Therapy.
The authors tagged it with the keywords hepatocellular carcinoma, lanreotide, survival and transarterial chemoembolisation.
What This Means in Plain Language
The paper is a randomized and pilot study of Somatostatin and Lanreotide in 71 patients over 3 years.
The publication is from 2017 (Oncotarget), a journal based in United States.
More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.
Our Notes on the Compounds
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Lanreotide: A long-acting 8-amino-acid somatostatin analog (Somatuline Depot) in the same class as octreotide.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.